Combretastatin Derivatives as Microtubule Inhibitors of Colchicines Binding Site

Abstract

: The colchicine binding site in microtubules is the most flourishing target for anti-cancer treatment. Microtubule inhibitor drugs, including paclitaxel and vinca alkaloids, have been considered to exert their activity primarily by increasing or decreasing the cellular micro-tubule mass. This review describes the microtubular assembly along with the combretastatin de-rivatives as microtubules inhibitors, the structures of compounds known to interact with colchi-cines binding sites, and their possible mechanism of action. Additionally, the utility of other heterocyclic rings and their combretastatin derivatives in treating cancer is also discussed. Col-chicines binding site represents a stimulating new molecular target in the design of com-bretastatin drugs.